$3.41
-0.13-3.67%
Ult. Agg.: Nov 17, 1:10 PM
Starling Oncology (STLN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $-0.13 | $-0.05 | -160.0 % |
| Q2 | Aug 6, 2026 | $-0.08 | $-0.06 | -33.3 % |
| Q1 | May 7, 2026 | $-0.02 | $-0.08 | 75.0 % |
| Q4 | Mar 12, 2026 | $-0.06 | $-0.09 | 33.3 % |
Quarterly Revenue (Billions)
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $169.77M | $168.59M | 0.70 % |
| Q2 | Aug 6, 2026 | $161.28M | $156.91M | 2.79 % |
| Q1 | May 7, 2026 | $147.44M | $142.63M | 3.38 % |
| Q4 | Mar 12, 2026 | $141.96M | $140.27M | 1.20 % |
Starling Oncology (STLN) ha pubblicato l'ultima guidance il novembre 5, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $650M - $660M per il periodo.
Rispetto alle previsioni precedenti, Starling Oncology ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Starling Oncology ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Starling Oncology. 2
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.05 | $-0.06 | $-0.08 | $-0.09 |
| Actual | $-0.13 | $-0.08 | $-0.02 | $-0.06 |
| Surprise | -160.0% | -33.3% | +75.0% | +33.3% |
| Revenue | ||||
| Estimate | $168.6M | $156.9M | $142.6M | $140.3M |
| Actual | $169.8M | $161.3M | $147.4M | $142.0M |
| Surprise | +0.70% | +2.79% | +3.38% | +1.20% |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.04 | $-0.05 |
| Revenue | ||
| Consensus | $177.6M | $197.5M |
